Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy

Experimental Neurology

Volumn 141, Issue 2, 1996, Pages 214-224

  Elliott, Peter J ^a   Hayward, Neil J ^a,d   Huff, Michael R ^a   Nagle, Tricia L ^a   Black, Keith L ^b   Bartus, Raymond T ^a,c  

^a ALKERMES INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Pharmaceutical Peptides Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ ANTAGONIST; BRADYKININ RECEPTOR AGONIST; CARBOPLATIN; ICATIBANT; LOBRADIMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CONTROLLED STUDY; DRUG BRAIN LEVEL; FEMALE; GLIOMA; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030271479     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1996.0156     Document Type: Article

References (67)

1. 1. BARTUS, R. T., P. ELLIOTT, N. HAYWARD, R. DEAN, E. L. MCEWEN, AND S. K. FISHER 1996. Permeability of the BBB by the bradykinin agonist, RMP-7: Evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology 33: 270-278.
2. 2. BARTUS, R. T., P. J. ELLIOTT, R. L. DEAN, N. J. HAYWARD, T. L. NAGLE, M. R. HUFF, P. A. SNODGRASS, AND D. G. BLUNT. 1996. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp. Neurol., in press.
3. 3. BLACK, K. L. 1995. Biochemical opening of the blood-brain barrier. Adv. Drug Rev. 15: 37-52.
4. 4. BREM, H., S. PIANTADOSI, P. C. BURGER, M. WALKER, R. SELKER, N. A. VICK, K. BLACK, M. SISTI, S. BREM, G. MOHR, P. MULLER, R. MORAWETZ, AND S. C. SCHOLD. 1995. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery of biodegradeable polymers of chemotherapy for recurrent gliomas. Lancet 345: 1008-1012.
5. 5. BRIGHTMAN, M. W., M. HORI, S. I. RAPOPORT, T. S. REESE, AND E. WESTERGAARD. 1973. Osmotic opening of tight junctions in cerebral endothelium. J. Comp. Neurol. 152: 317-326.
6. 6. CHANDLER, K. L., AND M. D. PRADOS. 1994. Chemotherapy of brain tumors: Clinical aspects. Pages 731-744 in R. A. Morantz and J. W. Walsh, Eds., Brain Tumors: A Comprehensive Text. Dekker, New York.
7. 7. CURRAN, W. J., C. B. SCOTT, J. HORTON, J. S. NELSON, A. S. WEINSTEIN, A. J. FISCHBACH, C. H. CHANG, M. ROTMAN, S. O. ASBELL, R. E. KRISCH, AND D. F. NELSON. 1993. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J. Natl. Cancer Inst. 85: 704-710.
8. 8. DE VITA, V. T. 1985. Principles of chemotherapy. Pages 257-286 in V. T. De Vita, S. Hellman, and S. A. Rosenberg, Eds., Cancer, Principles and Practice of Oncology. Lippincott, Philadelphia.
9. 9. DOCTROW, S. R., S. M. ABELLEIRA, L. A. CURRY, R. HELLER-HARRISON, J. W. KOZARICH, B. MALFROY, L. A. MCCARROL, K. G. MORGAN, A. R. MORROW, G. F. MUSSO, J. L. SMART, J. A. STRAUB, B. TURNBULL, AND C. A. GLOFF. 1994. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J. Pharmacol. Exp. Ther. 271: 229-237.
10. 10. DONELLI, M. G., M. ZUCCHETTI, AND M. D'INCALCI. 1992. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother. Pharmacol. 30: 251-260.
11. 11. DOROVINI-ZIS, K., P. D. BOWMAN, A. L. BETZ, AND G. W. GOLDSTEIN. 1984. Hyperosmotic arabinose solutions open tight junctions between brain capillary endothelial cells in tissue culture. Brain Res. 302: 383-386.
12. 12. ELLIOTT, P. J., N. J. HAYWARD, R. L. DEAN, D. G. BLUNT, AND R. T. BARTUS. 1996. Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res. 56: in press.
13. 13. ELLIOTT, P. J., N. J. HAYWARD, R. L. DEAN, AND R. T. BARTUS. 1996. Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology 33: 205-208.
14. 14. FlSHMAN, R. A. 1987. Is there a therapeutic role for osmotic breaching of the blood-brain barrier? Ann. Neurol. 22: 298-299. [Editorial].
15. 15. GAYNON, P. S. 1994. Carboplatin in pediatric malignancies. Semin. Oncol. 21: 65-76.
16. 16. GREENBERG, H. S., W. D. ENSMINGER, W. F. CHANDLER, P. B. LAYTON, L. JUNCK, J. KNAKE, AND A. K. VINE. 1984. Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system. J. Neurosurg. 61: 423-429.
17. 17. GROOTHIUS, D. R., J. R. FISCHER, G. LAPIN, D. D. BIGNER, AND N. A. VlCK. 1982. Permeability of different experimental brain tumor models to horseradish peroxidase. J. Neuropathol. Exp. Neurol. 41:164-185.
18. 18. GUMERLOCK, M. K., AND E. A. NEUWELT. 1994. Chemotherapy of brain tumors: Innovative approaches. Pages 763-778 in R. A. Morantz and J. W. Walsh, Eds., Brain Tumors: A Comprehensive Text. Dekker, New York.
19. 19. HIESIGER, E. M., S. B. GREEN, W. R. SHAPIRO, P. C. BURGER, R. G. SELKER, M. S. MAHALEY, J. RANSOHOFF, J. C. VANGILDER, J. MEALEY, J. T. ROBERTSON, F. H. HOCHBERG, AND R. F. YOUNG. 1995. Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group Trial 8420A. J. Neuro-Oncol. 25: 143-154.
20. 14C-MTX) delivery by intravenous vs intracarotid (IC) route without or with IC mannitol in experimental rat brain tumors as measured by quantitative autoradiography (QAR). Proc. Am. Assoc. Cancer Res. 25: 363.
21. 21. HIESIGER, E. M., R. M. VOORHIES, G. A. BASLER, L. E. LIPSCHUTZ, J. B. POSNER, AND W. R. SHAPIRO. 1986. Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: The effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann. Neurol. 19: 50-59.
22. 22. HIRANO, A., AND T. MATSUI. 1975. Vascular structures in brain tumors. Hum. Pathol. 6: 611-621.
23. 23. HOCK, F. J., K. WIRTH, U. ALBUS, W. LINZ, G. GERHARDS, ST. WIEMER-HENKE, G. BREIPOHL, W. KÖNIG, J. KNOLLE, AND B. A. SCHÖLKENS. 1991. Hoe 140 a new potent and long acting bradykinin-antagonist: In vitro studies. Br. J. Pharmacol. 102: 769-773.
24. 24. INAMURA, T., AND K. L. BLACK. 1994. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J. Cereb. Blood Flow Metab. 14: 862-870.
25. 25. INAMURA, T., T. NOMURA, R. T. BARTUS, AND K. L. BLACK. 1994. Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors. J. Neurosurg. 81: 752-758.
26. 26. INOUE, T., M. FUKUI, S. NISHIO, K. KITAMURA, AND H. NAGARA. 1987. Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. J. Neurosurg. 66: 256-263.
27. 27. KAPLAN, R. S., AND P. H. WIERNICK. 1982. Neurotoxicity of antineoplastic drugs. Semin. Oncol. 9: 103-109.
28. 28. LARNER, J. M., C. D. PHILLIPS, J. E. DION, M. E. JENSEN, S. A. NEWMAN, AND J. A. JANE. 1995. Aphase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas. Am. J. Clin. Oncol. 18: 1-7.
29. 29. LEVIN, V. A., P. SILVER, J. HANNIGAN, W. M. WARA, P. H. GUTIN, R. L. DAVIS, AND C. B. WILSON. 1990. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18: 321-324.
30. 30. LEVIN, V. A., W. M. WARA, R. L. DAVIS, P. VESTNYS, K. J. RESSER, K. YATSKO, S. NUTIK, P. H. GUTIN, AND C. B. WILSON. 1985. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J. Neurosurg. 63: 218-223.
31. 31. LONG, D. M. 1970. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J. Neurosurg. 32: 127-144.
32. 32. MARTINS, M. A., C. P. PASQUALE, P. T. BOZZA, P. M. SILVA, H. C. FARIA NETO, AND R. S. CORDEIRO. 1992. Homologous tachyphylaxis to bradykinin and its interference with allergic pleurisy in actively sensitized rats. Eur. J. Pharmacol. 220: 55-61.
33. 33. MATSUKADO, K., T. INAMURA, S. NAKANO, M. FUKUI, R. T. BARTUS, AND K. L. BLACK. 1996. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery, 39: 125-134.
34. 34. MEISWALA, A. H., M. NAKAGAWA, G. T. GOBBEL, ET AL. 1996. Passage of iodinated contrast medium through the damaged blood-brain barrier is enhanced by the bradykinin analog RMP-7. Submitted for publication.
35. 35. MUNOZ, C. M., AND L. M. F. LEE-LUNDBERG. 1992. Receptor-mediated internalization of bradykinin. J. Biol. Chem. 267: 303-309.
36. 36. NAKAGAWA, H., D. GROOTHUIS, AND R. G. BLASBERG. 1984. The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas. Neurology 34: 1571-1581.
37. 37. NELSON, D. F., J. V. MCDONALD, L. W. LAPHAM, R. QAZI, AND P. RUBIN. 1992. Central nervous system tumors. Pages 617-644 in R. Rubin, S. McDonald, and R. Qazi, Eds., Clinical Oncology., Saunders, Philadelphia.
38. 38. NEUWELT, E. A., AND S. I. RAPOPORT. 1984. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc. 43: 214-219.
39. 39. NEUWELT, E. A., P. A. BARNETT, D. D. BIGNER, AND E. P. FENKEL. 1982. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: The factor of the blood-brain barrier. Proc. Natl. Acad. Sci. USA 79: 4420-4423.
40. 40. NEUWELT, E. A., P. A. BARNETT, C. I. MCCORMICK, E. P. FRENKEL, AND J. D. MINNA. 1985. Osmotic blood-brain barrier modification: Monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery 17: 419-423.
41. 41. NEUWELT, E. A., S. A. HILL, AND E. P. FRENKEL. 1984. Osmotic blood-brain barrier modification and combination chemotherapy: Concurrent tumor regression in areas of barrier opening. Neurosurgery 15: 362-366.
42. 42. NOMURA, T., T. INAMURA, AND K. L. BLACK. 1994. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res. 659: 62-66.
43. 43. OHNO, K., K. O. PETTIGREW, AND S. I. RAPOPORT. 1978. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. 253: H299-H307.
44. 44. OZOLS, R. F., B. C. BEHRENS, Y. OSTCHEGA, AND R. C. YOUNG. 1985. High dose cisplatin and high dose carboplatin in refractory ovarian cancer. Cancer Treat. Rev. 12: 59-65.
45. 45. PELLEGRINO, L. J., A. S. PELLEGRINO, AND A. J. CUSHMAN. 1986. A Stereotaxic Atlas of the Rat Brain, 2nd ed. Plenum, New York.
46. 46. POISSON, M., Y. PEREON, J. CHIRAS, AND J. Y. DELATTRE. 1991. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J. Neuro-Oncol. 10: 139-144.
47. 47. POLOSA, R., K. RAJAKULASINGAM, G. PROSPERINI, L. V. MILAZZO, G. SANTONOCITO, AND S. T. HOLGATE. 1993. Cross-tachyphylactic airway response to inhaled bradykinin, kallidin and [desArg9]bradykinin in asthmatic subjects. Eur. Respir. J. 6: 687-693.
48. 48. RADHAKRISHMAN, K., N. I. BOHNEN, AND L. T. KURLAND. 1994. Epidemiology of brain tumors. Pages 1-18 in R. A. Morantz and J. W. Walsh, Eds., Brain Tumors: A Comprehensive Text. Dekker, New York.
49. 49. RILEY, M. G. I., N. N. KIM, V. E. WATSON, Y. P. GOBIN, C. P. LEBEL, K. L. BLACK, AND R. T. BARTUS. 1996. Intraarterial administration of the bradykinin agonist, RMP-7 and carboplatin: A toxicologic evaluation in swine. Submitted for publication.
50. 50. ROZENCWEIG, M., D. D. VON HOFF, M. SLAVIK, AND F. M. MUGGIA. 1977. Cis-diamminedichloroplatinum(II): A new anti-cancer drug. Ann. Intern. Med. 86: 803-812.
51. 51. SANOVICH, E., R. T. BARTUS, P. F. FRIDEN, R. L. DEAN, H. Q. LE, AND M. W. BRIGHTMAN. 1995. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 705: 125-135.
52. 52. SHAPIRO, W. R., AND J. R. SHAPIRO. 1986. Principles of brain tumor chemotherapy. Semin. Oncol. 13: 56-69.
53. 53. SHAPIRO, W. R., S. B. GREEN, P. C. BURGER, R. G. SELKER, J. C. VANGILDER, J. T. ROBERTSON, J. MEALEY, J. RANSOGFF, AND M. S. MAHALEY. 1992. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J. Neurosurg. 76: 772-781.
54. 54. SHIBATA, S. 1989. Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol. 78: 561-571.
55. 55. STEWART, D. J., J. M. BELANGER, Z. GRAHOVAC, S. CURUVIJA, L. R. GIONET, S. E. AITKEN, H. HUGENHOLTZ, B. G. BENOIT, AND V. F. DASlLVA. 1992. Phase I study of intracarotid administration of carboplatin. Neurosurgery 30: 512-516.
56. 56. STEWART, D. J., R. S. BENJAMIN, S. ZIMMERMAN, R. M. CAPRIOLLI, S. WALLACE, V. CHUANG, D. CALVO, M. SAMUELS, J. BONURA, AND T. L. LOO. 1983. Clinical pharmacology of intraarterial cisdiamminedichloroplatinum(II). Cancer Res. 43: 917-920.
57. 57. STRÄUB, J. A., A. AKIYAMA, AND P. PARMAR 1994. In vitro plasma metabolism of RMP-7. Pharm. Res. 11: 1673-1676.
58. 58. TOMIWA, K., F. HAZAMA, AND H. MIKAWA. 1983. Neurotoxicity of vincristine after osmotic opening of the blood-brain barrier. Neuropathol. Appl. Neurobiol. 9: 345-354.
59. 59. VAN DER VIJGH, W. J. F. 1991. Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21: 242-261.
60. 60. WALKER, R. W., E. DANTIS, AND W. R. SHAPIRO. 1987. Treatment of recurrent glioma with carboplatin. Proc. Am. Soc. Clin. Oncol. 6.
61. 61. WARNICK, R. E., M. D. PRADOS, E. E. MACK, K. L. CHANDLER, F. DOZ, J. E. RABBITT, AND M. K. MALEC. 1994. Aphase II study of intravenous carboplatin for the treatment of recurrent gliomas. J. Neuro-Oncol. 19(1): 69-74.
62. 62. WARNKE, P. C., R. G. BLASBERG, AND D. R. GROOTHUIS. 1987. The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann. Neurol. 22: 330-335.
63. 63. WILLIAMS, P. C., W. D. HENNER, S. ROMAN-GOLDSTEIN, S. A. DAHLBORG, R. E. BRUMMETT, M. TABLEMAN, B. W. DANA, AND E. A. NEUWELT. 1995. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37:17-28.
64. 10-[HOE140]) is a potent bradykinin B1 receptor antagonist. Eur. J. Pharmacol. 205: 217-218.
65. 65. WIRTH, K., F. V. HOCK, U. ALBUS, W LINZ, H. G. ALPERMANN, H. ANAGNOSTOPULOS, G. ST. HENKE, W. BREIPHOL, W. KÖNIG, J. KNOLLE, AND B. A. SCHÖLKENS. 1991. Hoe 140, a new potent and long acting bradykinin-antagonist: In vivo studies. Br. J. Pharmacol. 102: 774-777.
66. 66. YUNG, W. K., L. MECHTLER, AND M. J. GLEASON. 1991. Intravenous carboplatin for recurrent malignant glioma: A phase II study. J. Clin. Oncol. 9: 860-864.
67. 67. ZIYLAN, Y. Z., J. M. LEFAUCONNIER, G. BERNARD, AND J. M. BOURRE. 1988. Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood-brain barrier. J. Neurochem. 51: 1338-1342.